



For immediate release

16 April 2007

## **Galapagos signs two new drug discovery collaborations with Ono Pharmaceutical**

**Mechelen, Belgium and Osaka, Japan; 16 April 2007 – Galapagos NV (Euronext & LSE: GLPG) announced today that its BioFocus DPI service division has signed two new collaborations with Ono Pharmaceutical Company Ltd. (Tokyo: OSA). These collaborations build on the successful relationship between Ono and DPI, which began in 2004. Under the first collaboration announced today, BioFocus DPI will use selected compounds from its SoftFocus and other synthetic small molecule collections to perform high throughput screening for Ono's drug discovery program. In the second collaboration, BioFocus DPI will apply its medicinal and computational chemistry and ADME profiling expertise in multiple medicinal chemistry projects for Ono.**

"We are pleased with the new contracts with Ono that build on the longstanding relationship between Ono and DPI. The new contracts show the benefit of building a global drug discovery service business. We combine expertise from our acquired companies Discovery Partners International, BioFocus as well as Inpharmatica, realizing the synergy in bringing these activities together," added Onno van de Stolpe, Chief Executive Officer of Galapagos.

"We are dedicated to creating innovative medicines," said Dr. Daikichi Fukushima, Managing Director, Ono. "Accordingly, we are enthusiastic about extending the relationship with BioFocus DPI, a leading company in drug discovery, so that we can continue creating novel drug candidates."

### **About Galapagos**

Galapagos (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA; London AiM: GLPG) is a drug discovery company with clinical and pre-clinical programs in bone and joint diseases, cachexia, and menopausal hot flashes. Its division BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. BioFocus DPI also provides adenoviral reagents for rapid identification and validation of novel drug targets, compound libraries for drug screening as well as chemogenomics and ADMET<sup>1</sup> database products to select targets and compounds. Galapagos currently employs 450 people and operates facilities in eight countries, with global headquarters in Mechelen, Belgium. More information about Galapagos and BioFocus DPI can be found at [www.glpj.com](http://www.glpj.com).

### **CONTACT**

Galapagos NV  
Onno van de Stolpe, CEO  
Tel: +31 6 2909 8028  
[ir@glpg.com](mailto:ir@glpg.com)

---

<sup>1</sup> ADMET is the acronym for Absorption, Distribution, Metabolism, Excretion, and Toxicity: Meeting parameters against these five criteria is critical to the success of a pharmaceutical compound as a drug.

Galapagos



*This release may contain forward-looking statements, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “could,” “stands to,” and “continues,” as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.*